nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluvoxamine—CYP2C9—brain cancer	0.487	1	CbGaD
Fluvoxamine—CYP2D6—Lomustine—brain cancer	0.0512	0.174	CbGbCtD
Fluvoxamine—CYP1A2—Carmustine—brain cancer	0.0506	0.172	CbGbCtD
Fluvoxamine—CYP2D6—Hydroxyurea—brain cancer	0.0388	0.132	CbGbCtD
Fluvoxamine—CYP3A4—Temozolomide—brain cancer	0.0383	0.13	CbGbCtD
Fluvoxamine—CYP3A4—Lomustine—brain cancer	0.0325	0.111	CbGbCtD
Fluvoxamine—CYP2E1—Etoposide—brain cancer	0.026	0.0884	CbGbCtD
Fluvoxamine—CYP3A5—Etoposide—brain cancer	0.0202	0.0687	CbGbCtD
Fluvoxamine—CYP1A2—Etoposide—brain cancer	0.015	0.0511	CbGbCtD
Fluvoxamine—ABCB1—Etoposide—brain cancer	0.0131	0.0447	CbGbCtD
Fluvoxamine—CYP3A4—Etoposide—brain cancer	0.00786	0.0268	CbGbCtD
Fluvoxamine—SLC6A3—telencephalic ventricle—brain cancer	0.00194	0.0943	CbGeAlD
Fluvoxamine—SLC6A3—Dopaminergic Neurogenesis—OTX2—brain cancer	0.00157	0.0359	CbGpPWpGaD
Fluvoxamine—CYP1A1—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00144	0.0329	CbGpPWpGaD
Fluvoxamine—CYP1A1—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00131	0.03	CbGpPWpGaD
Fluvoxamine—SLC6A3—ganglion—brain cancer	0.00121	0.0587	CbGeAlD
Fluvoxamine—CYP2B6—CYP2E1 reactions—CYP2C9—brain cancer	0.00121	0.0276	CbGpPWpGaD
Fluvoxamine—CYP2E1—CYP2E1 reactions—CYP2C9—brain cancer	0.00118	0.0271	CbGpPWpGaD
Fluvoxamine—CYP2C19—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.00118	0.0269	CbGpPWpGaD
Fluvoxamine—SLC6A4—ganglion—brain cancer	0.0011	0.0538	CbGeAlD
Fluvoxamine—CYP2C19—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.00107	0.0245	CbGpPWpGaD
Fluvoxamine—SLC6A4—Synaptic Vesicle Pathway—SYP—brain cancer	0.00102	0.0234	CbGpPWpGaD
Fluvoxamine—CYP3A7—Xenobiotics—CYP2C9—brain cancer	0.00101	0.0232	CbGpPWpGaD
Fluvoxamine—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP2C9—brain cancer	0.000916	0.021	CbGpPWpGaD
Fluvoxamine—SLC6A3—hindbrain—brain cancer	0.000914	0.0445	CbGeAlD
Fluvoxamine—CYP2C19—CYP2E1 reactions—CYP2C9—brain cancer	0.000911	0.0209	CbGpPWpGaD
Fluvoxamine—SLC6A4—hindbrain—brain cancer	0.000838	0.0408	CbGeAlD
Fluvoxamine—CYP2D6—CYP2E1 reactions—CYP2C9—brain cancer	0.000838	0.0192	CbGpPWpGaD
Fluvoxamine—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP2C9—brain cancer	0.000833	0.0191	CbGpPWpGaD
Fluvoxamine—CYP2B6—Xenobiotics—CYP2C9—brain cancer	0.000747	0.0171	CbGpPWpGaD
Fluvoxamine—CYP2E1—Xenobiotics—CYP2C9—brain cancer	0.000732	0.0168	CbGpPWpGaD
Fluvoxamine—CYP3A5—Xenobiotics—CYP2C9—brain cancer	0.00073	0.0167	CbGpPWpGaD
Fluvoxamine—CYP2E1—Tamoxifen metabolism—CYP2C9—brain cancer	0.000704	0.0161	CbGpPWpGaD
Fluvoxamine—CYP3A5—Tamoxifen metabolism—CYP2C9—brain cancer	0.000702	0.0161	CbGpPWpGaD
Fluvoxamine—CYP1A1—Xenobiotics—CYP2C9—brain cancer	0.00069	0.0158	CbGpPWpGaD
Fluvoxamine—SLC6A3—Dopaminergic Neurogenesis—GLI2—brain cancer	0.000681	0.0156	CbGpPWpGaD
Fluvoxamine—CYP1A1—Tamoxifen metabolism—CYP2C9—brain cancer	0.000664	0.0152	CbGpPWpGaD
Fluvoxamine—SLC6A3—Dopaminergic Neurogenesis—GLI1—brain cancer	0.000641	0.0147	CbGpPWpGaD
Fluvoxamine—CYP2C19—Xenobiotics—CYP2C9—brain cancer	0.000565	0.0129	CbGpPWpGaD
Fluvoxamine—CYP2C19—Tamoxifen metabolism—CYP2C9—brain cancer	0.000543	0.0124	CbGpPWpGaD
Fluvoxamine—SLC6A3—brainstem—brain cancer	0.000524	0.0255	CbGeAlD
Fluvoxamine—CYP2D6—Xenobiotics—CYP2C9—brain cancer	0.000519	0.0119	CbGpPWpGaD
Fluvoxamine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000513	0.0118	CbGpPWpGaD
Fluvoxamine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000501	0.0115	CbGpPWpGaD
Fluvoxamine—CYP2D6—Tamoxifen metabolism—CYP2C9—brain cancer	0.000499	0.0114	CbGpPWpGaD
Fluvoxamine—CYP3A7—endocrine gland—brain cancer	0.000499	0.0243	CbGeAlD
Fluvoxamine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000489	0.0112	CbGpPWpGaD
Fluvoxamine—SLC6A4—brainstem—brain cancer	0.00048	0.0234	CbGeAlD
Fluvoxamine—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000479	0.011	CbGpPWpGaD
Fluvoxamine—SLC6A3—telencephalon—brain cancer	0.000465	0.0227	CbGeAlD
Fluvoxamine—SLC6A3—Dopaminergic Neurogenesis—SHH—brain cancer	0.000463	0.0106	CbGpPWpGaD
Fluvoxamine—CYP1A2—Xenobiotics—CYP2C9—brain cancer	0.00044	0.0101	CbGpPWpGaD
Fluvoxamine—SLC6A4—telencephalon—brain cancer	0.000426	0.0208	CbGeAlD
Fluvoxamine—SIGMAR1—telencephalon—brain cancer	0.000423	0.0206	CbGeAlD
Fluvoxamine—CYP1A2—Tamoxifen metabolism—CYP2C9—brain cancer	0.000423	0.0097	CbGpPWpGaD
Fluvoxamine—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00042	0.00962	CbGpPWpGaD
Fluvoxamine—CYP3A7—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000414	0.00949	CbGpPWpGaD
Fluvoxamine—CYP2D6—hindbrain—brain cancer	0.000404	0.0197	CbGeAlD
Fluvoxamine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000388	0.00889	CbGpPWpGaD
Fluvoxamine—ABCB1—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000378	0.00867	CbGpPWpGaD
Fluvoxamine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.00036	0.00826	CbGpPWpGaD
Fluvoxamine—SIGMAR1—pituitary gland—brain cancer	0.000345	0.0168	CbGeAlD
Fluvoxamine—CYP3A7—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00034	0.0078	CbGpPWpGaD
Fluvoxamine—CYP3A4—Xenobiotics—CYP2C9—brain cancer	0.00034	0.00778	CbGpPWpGaD
Fluvoxamine—SLC6A3—midbrain—brain cancer	0.000334	0.0163	CbGeAlD
Fluvoxamine—SIGMAR1—medulla oblongata—brain cancer	0.000333	0.0162	CbGeAlD
Fluvoxamine—CYP1A1—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000331	0.0076	CbGpPWpGaD
Fluvoxamine—CYP3A4—Tamoxifen metabolism—CYP2C9—brain cancer	0.000327	0.00749	CbGpPWpGaD
Fluvoxamine—SLC6A3—spinal cord—brain cancer	0.000326	0.0159	CbGeAlD
Fluvoxamine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.00031	0.00711	CbGpPWpGaD
Fluvoxamine—CYP2B6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000306	0.00702	CbGpPWpGaD
Fluvoxamine—SLC6A4—midbrain—brain cancer	0.000306	0.0149	CbGeAlD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—HES5—brain cancer	0.000306	0.00701	CbGpPWpGaD
Fluvoxamine—ABCB1—blood vessel—brain cancer	0.000305	0.0148	CbGeAlD
Fluvoxamine—SIGMAR1—midbrain—brain cancer	0.000304	0.0148	CbGeAlD
Fluvoxamine—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000304	0.00697	CbGpPWpGaD
Fluvoxamine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000303	0.00695	CbGpPWpGaD
Fluvoxamine—CYP2E1—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.0003	0.00688	CbGpPWpGaD
Fluvoxamine—CYP3A5—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000299	0.00686	CbGpPWpGaD
Fluvoxamine—SLC6A4—spinal cord—brain cancer	0.000299	0.0145	CbGeAlD
Fluvoxamine—SIGMAR1—spinal cord—brain cancer	0.000297	0.0144	CbGeAlD
Fluvoxamine—SLC6A3—head—brain cancer	0.00029	0.0141	CbGeAlD
Fluvoxamine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000288	0.0066	CbGpPWpGaD
Fluvoxamine—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000286	0.00657	CbGpPWpGaD
Fluvoxamine—CYP1A1—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000283	0.00648	CbGpPWpGaD
Fluvoxamine—CYP2C19—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000271	0.00622	CbGpPWpGaD
Fluvoxamine—SLC6A4—endocrine gland—brain cancer	0.000269	0.0131	CbGeAlD
Fluvoxamine—SLC6A4—head—brain cancer	0.000265	0.0129	CbGeAlD
Fluvoxamine—SLC6A3—central nervous system—brain cancer	0.000264	0.0129	CbGeAlD
Fluvoxamine—CYP2E1—telencephalon—brain cancer	0.00026	0.0126	CbGeAlD
Fluvoxamine—SLC6A3—cerebellum—brain cancer	0.000258	0.0126	CbGeAlD
Fluvoxamine—SLC6A4—Circadian rythm related genes—NTRK3—brain cancer	0.000258	0.00591	CbGpPWpGaD
Fluvoxamine—CYP3A5—Irinotecan Pathway—APC—brain cancer	0.000258	0.00591	CbGpPWpGaD
Fluvoxamine—CYP2B6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000252	0.00577	CbGpPWpGaD
Fluvoxamine—CYP2E1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000246	0.00565	CbGpPWpGaD
Fluvoxamine—CYP3A5—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000246	0.00564	CbGpPWpGaD
Fluvoxamine—SLC6A3—Parkinsons Disease Pathway—CCNE1—brain cancer	0.000244	0.00559	CbGpPWpGaD
Fluvoxamine—SLC6A4—central nervous system—brain cancer	0.000242	0.0118	CbGeAlD
Fluvoxamine—SIGMAR1—cerebellum—brain cancer	0.000235	0.0115	CbGeAlD
Fluvoxamine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000234	0.00538	CbGpPWpGaD
Fluvoxamine—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2C9—brain cancer	0.000233	0.00534	CbGpPWpGaD
Fluvoxamine—CYP1A1—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000232	0.00532	CbGpPWpGaD
Fluvoxamine—CYP2D6—brainstem—brain cancer	0.000232	0.0113	CbGeAlD
Fluvoxamine—CYP2C19—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000231	0.0053	CbGpPWpGaD
Fluvoxamine—CYP2B6—gonad—brain cancer	0.000231	0.0112	CbGeAlD
Fluvoxamine—Hypotension—Procarbazine—brain cancer	0.000225	0.00145	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Temozolomide—brain cancer	0.000224	0.00144	CcSEcCtD
Fluvoxamine—CYP2C19—endocrine gland—brain cancer	0.000223	0.0109	CbGeAlD
Fluvoxamine—Stomatitis—Temozolomide—brain cancer	0.000222	0.00144	CcSEcCtD
Fluvoxamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2C9—brain cancer	0.000222	0.00509	CbGpPWpGaD
Fluvoxamine—Urinary tract infection—Temozolomide—brain cancer	0.000222	0.00143	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Procarbazine—brain cancer	0.000219	0.00142	CcSEcCtD
Fluvoxamine—Insomnia—Procarbazine—brain cancer	0.000218	0.0014	CcSEcCtD
Fluvoxamine—Paraesthesia—Procarbazine—brain cancer	0.000216	0.00139	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Temozolomide—brain cancer	0.000216	0.00139	CcSEcCtD
Fluvoxamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000216	0.00494	CbGpPWpGaD
Fluvoxamine—Sinusitis—Temozolomide—brain cancer	0.000214	0.00138	CcSEcCtD
Fluvoxamine—Somnolence—Procarbazine—brain cancer	0.000214	0.00138	CcSEcCtD
Fluvoxamine—Toxic epidermal necrolysis—Etoposide—brain cancer	0.000213	0.00138	CcSEcCtD
Fluvoxamine—Haemoglobin—Carmustine—brain cancer	0.000213	0.00137	CcSEcCtD
Fluvoxamine—CYP2D6—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000213	0.00488	CbGpPWpGaD
Fluvoxamine—Haemorrhage—Carmustine—brain cancer	0.000212	0.00137	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Hydroxyurea—brain cancer	0.000212	0.00137	CcSEcCtD
Fluvoxamine—CYP1A2—Arachidonic acid metabolism—CYP2C9—brain cancer	0.000211	0.00485	CbGpPWpGaD
Fluvoxamine—Anaemia—Hydroxyurea—brain cancer	0.000211	0.00136	CcSEcCtD
Fluvoxamine—Hypoaesthesia—Carmustine—brain cancer	0.000211	0.00136	CcSEcCtD
Fluvoxamine—Hallucination—Carmustine—brain cancer	0.000211	0.00136	CcSEcCtD
Fluvoxamine—SLC6A3—brain—brain cancer	0.00021	0.0102	CbGeAlD
Fluvoxamine—Decreased appetite—Procarbazine—brain cancer	0.000209	0.00135	CcSEcCtD
Fluvoxamine—Oedema peripheral—Carmustine—brain cancer	0.000209	0.00135	CcSEcCtD
Fluvoxamine—Fatigue—Procarbazine—brain cancer	0.000207	0.00134	CcSEcCtD
Fluvoxamine—Haemoglobin—Temozolomide—brain cancer	0.000206	0.00133	CcSEcCtD
Fluvoxamine—Malaise—Hydroxyurea—brain cancer	0.000206	0.00133	CcSEcCtD
Fluvoxamine—Pain—Procarbazine—brain cancer	0.000206	0.00133	CcSEcCtD
Fluvoxamine—Constipation—Procarbazine—brain cancer	0.000206	0.00133	CcSEcCtD
Fluvoxamine—CYP2D6—telencephalon—brain cancer	0.000205	0.01	CbGeAlD
Fluvoxamine—Haemorrhage—Temozolomide—brain cancer	0.000205	0.00132	CcSEcCtD
Fluvoxamine—Hepatitis—Temozolomide—brain cancer	0.000205	0.00132	CcSEcCtD
Fluvoxamine—Dysphagia—Etoposide—brain cancer	0.000205	0.00132	CcSEcCtD
Fluvoxamine—Leukopenia—Hydroxyurea—brain cancer	0.000204	0.00132	CcSEcCtD
Fluvoxamine—Visual impairment—Carmustine—brain cancer	0.000204	0.00132	CcSEcCtD
Fluvoxamine—CYP2E1—medulla oblongata—brain cancer	0.000204	0.00993	CbGeAlD
Fluvoxamine—Hypoaesthesia—Temozolomide—brain cancer	0.000204	0.00132	CcSEcCtD
Fluvoxamine—Hallucination—Temozolomide—brain cancer	0.000204	0.00132	CcSEcCtD
Fluvoxamine—Pharyngitis—Temozolomide—brain cancer	0.000203	0.00131	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Temozolomide—brain cancer	0.000202	0.00131	CcSEcCtD
Fluvoxamine—Oedema peripheral—Temozolomide—brain cancer	0.000202	0.0013	CcSEcCtD
Fluvoxamine—Urethral disorder—Temozolomide—brain cancer	0.000201	0.0013	CcSEcCtD
Fluvoxamine—Sweating increased—Etoposide—brain cancer	0.000199	0.00129	CcSEcCtD
Fluvoxamine—Feeling abnormal—Procarbazine—brain cancer	0.000198	0.00128	CcSEcCtD
Fluvoxamine—Eye disorder—Carmustine—brain cancer	0.000198	0.00128	CcSEcCtD
Fluvoxamine—Convulsion—Hydroxyurea—brain cancer	0.000198	0.00128	CcSEcCtD
Fluvoxamine—Visual impairment—Temozolomide—brain cancer	0.000197	0.00127	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Procarbazine—brain cancer	0.000197	0.00127	CcSEcCtD
Fluvoxamine—Erythema multiforme—Temozolomide—brain cancer	0.000194	0.00125	CcSEcCtD
Fluvoxamine—SLC6A4—brain—brain cancer	0.000192	0.00937	CbGeAlD
Fluvoxamine—Discomfort—Hydroxyurea—brain cancer	0.000192	0.00124	CcSEcCtD
Fluvoxamine—Eye disorder—Temozolomide—brain cancer	0.000191	0.00124	CcSEcCtD
Fluvoxamine—Urticaria—Procarbazine—brain cancer	0.000191	0.00123	CcSEcCtD
Fluvoxamine—SIGMAR1—brain—brain cancer	0.000191	0.0093	CbGeAlD
Fluvoxamine—Tinnitus—Temozolomide—brain cancer	0.000191	0.00123	CcSEcCtD
Fluvoxamine—Abdominal pain—Procarbazine—brain cancer	0.00019	0.00123	CcSEcCtD
Fluvoxamine—Body temperature increased—Procarbazine—brain cancer	0.00019	0.00123	CcSEcCtD
Fluvoxamine—CYP2C19—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.00019	0.00436	CbGpPWpGaD
Fluvoxamine—Cardiac disorder—Temozolomide—brain cancer	0.00019	0.00123	CcSEcCtD
Fluvoxamine—Arrhythmia—Carmustine—brain cancer	0.000189	0.00122	CcSEcCtD
Fluvoxamine—Alopecia—Carmustine—brain cancer	0.000187	0.00121	CcSEcCtD
Fluvoxamine—Oedema—Hydroxyurea—brain cancer	0.000186	0.0012	CcSEcCtD
Fluvoxamine—Angiopathy—Temozolomide—brain cancer	0.000186	0.0012	CcSEcCtD
Fluvoxamine—Mental disorder—Carmustine—brain cancer	0.000186	0.0012	CcSEcCtD
Fluvoxamine—Infection—Hydroxyurea—brain cancer	0.000185	0.00119	CcSEcCtD
Fluvoxamine—Malnutrition—Carmustine—brain cancer	0.000184	0.00119	CcSEcCtD
Fluvoxamine—Chills—Temozolomide—brain cancer	0.000184	0.00119	CcSEcCtD
Fluvoxamine—Pneumonia—Etoposide—brain cancer	0.000184	0.00119	CcSEcCtD
Fluvoxamine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000183	0.00419	CbGpPWpGaD
Fluvoxamine—Nervous system disorder—Hydroxyurea—brain cancer	0.000183	0.00118	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Hydroxyurea—brain cancer	0.000182	0.00118	CcSEcCtD
Fluvoxamine—CYP1A2—endocrine gland—brain cancer	0.000182	0.00886	CbGeAlD
Fluvoxamine—CYP2E1—spinal cord—brain cancer	0.000182	0.00886	CbGeAlD
Fluvoxamine—Stevens-Johnson syndrome—Etoposide—brain cancer	0.000181	0.00117	CcSEcCtD
Fluvoxamine—Alopecia—Temozolomide—brain cancer	0.000181	0.00117	CcSEcCtD
Fluvoxamine—CYP3A7—Biological oxidations—CYP2C9—brain cancer	0.000181	0.00414	CbGpPWpGaD
Fluvoxamine—CYP1A2—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.00018	0.00413	CbGpPWpGaD
Fluvoxamine—Acute coronary syndrome—Etoposide—brain cancer	0.00018	0.00116	CcSEcCtD
Fluvoxamine—CYP1A1—endocrine gland—brain cancer	0.000179	0.00874	CbGeAlD
Fluvoxamine—Renal failure—Etoposide—brain cancer	0.000179	0.00116	CcSEcCtD
Fluvoxamine—Mental disorder—Temozolomide—brain cancer	0.000179	0.00116	CcSEcCtD
Fluvoxamine—Neuropathy peripheral—Etoposide—brain cancer	0.000179	0.00116	CcSEcCtD
Fluvoxamine—Myocardial infarction—Etoposide—brain cancer	0.000179	0.00116	CcSEcCtD
Fluvoxamine—CYP1A1—Oxidative Stress—SOD2—brain cancer	0.000179	0.0041	CbGpPWpGaD
Fluvoxamine—Back pain—Carmustine—brain cancer	0.000178	0.00115	CcSEcCtD
Fluvoxamine—Malnutrition—Temozolomide—brain cancer	0.000178	0.00115	CcSEcCtD
Fluvoxamine—CYP3A7—Metapathway biotransformation—CYP2C9—brain cancer	0.000178	0.00408	CbGpPWpGaD
Fluvoxamine—Jaundice—Etoposide—brain cancer	0.000178	0.00115	CcSEcCtD
Fluvoxamine—Stomatitis—Etoposide—brain cancer	0.000178	0.00115	CcSEcCtD
Fluvoxamine—Anorexia—Hydroxyurea—brain cancer	0.000178	0.00115	CcSEcCtD
Fluvoxamine—Hypersensitivity—Procarbazine—brain cancer	0.000177	0.00114	CcSEcCtD
Fluvoxamine—CYP1A1—head—brain cancer	0.000177	0.00863	CbGeAlD
Fluvoxamine—CYP3A5—endocrine gland—brain cancer	0.000175	0.00855	CbGeAlD
Fluvoxamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000175	0.00401	CbGpPWpGaD
Fluvoxamine—Dysgeusia—Temozolomide—brain cancer	0.000175	0.00113	CcSEcCtD
Fluvoxamine—CYP2B6—endocrine gland—brain cancer	0.000174	0.00849	CbGeAlD
Fluvoxamine—Vision blurred—Carmustine—brain cancer	0.000174	0.00112	CcSEcCtD
Fluvoxamine—Tremor—Carmustine—brain cancer	0.000173	0.00112	CcSEcCtD
Fluvoxamine—CYP2C9—endocrine gland—brain cancer	0.000173	0.00841	CbGeAlD
Fluvoxamine—Asthenia—Procarbazine—brain cancer	0.000173	0.00111	CcSEcCtD
Fluvoxamine—Hepatobiliary disease—Etoposide—brain cancer	0.000173	0.00111	CcSEcCtD
Fluvoxamine—Back pain—Temozolomide—brain cancer	0.000172	0.00111	CcSEcCtD
Fluvoxamine—CYP2B6—head—brain cancer	0.000172	0.00839	CbGeAlD
Fluvoxamine—Anaemia—Carmustine—brain cancer	0.00017	0.0011	CcSEcCtD
Fluvoxamine—Agranulocytosis—Etoposide—brain cancer	0.00017	0.0011	CcSEcCtD
Fluvoxamine—Pruritus—Procarbazine—brain cancer	0.00017	0.0011	CcSEcCtD
Fluvoxamine—Agitation—Carmustine—brain cancer	0.00017	0.00109	CcSEcCtD
Fluvoxamine—Vision blurred—Temozolomide—brain cancer	0.000168	0.00108	CcSEcCtD
Fluvoxamine—Tremor—Temozolomide—brain cancer	0.000167	0.00108	CcSEcCtD
Fluvoxamine—Dyspnoea—Hydroxyurea—brain cancer	0.000166	0.00107	CcSEcCtD
Fluvoxamine—Somnolence—Hydroxyurea—brain cancer	0.000166	0.00107	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Temozolomide—brain cancer	0.000165	0.00107	CcSEcCtD
Fluvoxamine—Leukopenia—Carmustine—brain cancer	0.000165	0.00107	CcSEcCtD
Fluvoxamine—Anaemia—Temozolomide—brain cancer	0.000165	0.00106	CcSEcCtD
Fluvoxamine—Diarrhoea—Procarbazine—brain cancer	0.000165	0.00106	CcSEcCtD
Fluvoxamine—Dyspepsia—Hydroxyurea—brain cancer	0.000164	0.00106	CcSEcCtD
Fluvoxamine—Agitation—Temozolomide—brain cancer	0.000164	0.00106	CcSEcCtD
Fluvoxamine—CYP2E1—endocrine gland—brain cancer	0.000164	0.00797	CbGeAlD
Fluvoxamine—Hypoaesthesia—Etoposide—brain cancer	0.000163	0.00105	CcSEcCtD
Fluvoxamine—Angioedema—Temozolomide—brain cancer	0.000163	0.00105	CcSEcCtD
Fluvoxamine—Decreased appetite—Hydroxyurea—brain cancer	0.000162	0.00105	CcSEcCtD
Fluvoxamine—Urinary tract disorder—Etoposide—brain cancer	0.000162	0.00104	CcSEcCtD
Fluvoxamine—CYP1A1—central nervous system—brain cancer	0.000162	0.00788	CbGeAlD
Fluvoxamine—CYP2E1—head—brain cancer	0.000162	0.00787	CbGeAlD
Fluvoxamine—Gastrointestinal disorder—Hydroxyurea—brain cancer	0.000161	0.00104	CcSEcCtD
Fluvoxamine—Malaise—Temozolomide—brain cancer	0.000161	0.00104	CcSEcCtD
Fluvoxamine—Urethral disorder—Etoposide—brain cancer	0.000161	0.00104	CcSEcCtD
Fluvoxamine—Fatigue—Hydroxyurea—brain cancer	0.000161	0.00104	CcSEcCtD
Fluvoxamine—Vertigo—Temozolomide—brain cancer	0.00016	0.00103	CcSEcCtD
Fluvoxamine—Convulsion—Carmustine—brain cancer	0.00016	0.00103	CcSEcCtD
Fluvoxamine—Leukopenia—Temozolomide—brain cancer	0.00016	0.00103	CcSEcCtD
Fluvoxamine—Hypertension—Carmustine—brain cancer	0.000159	0.00103	CcSEcCtD
Fluvoxamine—Constipation—Hydroxyurea—brain cancer	0.000159	0.00103	CcSEcCtD
Fluvoxamine—Pain—Hydroxyurea—brain cancer	0.000159	0.00103	CcSEcCtD
Fluvoxamine—Dizziness—Procarbazine—brain cancer	0.000159	0.00103	CcSEcCtD
Fluvoxamine—Palpitations—Temozolomide—brain cancer	0.000158	0.00102	CcSEcCtD
Fluvoxamine—CYP2B6—central nervous system—brain cancer	0.000157	0.00765	CbGeAlD
Fluvoxamine—Chest pain—Carmustine—brain cancer	0.000157	0.00101	CcSEcCtD
Fluvoxamine—Myalgia—Carmustine—brain cancer	0.000157	0.00101	CcSEcCtD
Fluvoxamine—Anxiety—Carmustine—brain cancer	0.000156	0.00101	CcSEcCtD
Fluvoxamine—Cough—Temozolomide—brain cancer	0.000156	0.001	CcSEcCtD
Fluvoxamine—Erythema multiforme—Etoposide—brain cancer	0.000155	0.001	CcSEcCtD
Fluvoxamine—Convulsion—Temozolomide—brain cancer	0.000154	0.000997	CcSEcCtD
Fluvoxamine—Hypertension—Temozolomide—brain cancer	0.000154	0.000993	CcSEcCtD
Fluvoxamine—Feeling abnormal—Hydroxyurea—brain cancer	0.000153	0.000991	CcSEcCtD
Fluvoxamine—Eye disorder—Etoposide—brain cancer	0.000153	0.000989	CcSEcCtD
Fluvoxamine—Vomiting—Procarbazine—brain cancer	0.000153	0.000988	CcSEcCtD
Fluvoxamine—CYP1A1—Estrogen Receptor Pathway—STAT3—brain cancer	0.000153	0.00351	CbGpPWpGaD
Fluvoxamine—Cardiac disorder—Etoposide—brain cancer	0.000152	0.000982	CcSEcCtD
Fluvoxamine—Confusional state—Carmustine—brain cancer	0.000152	0.00098	CcSEcCtD
Fluvoxamine—Arthralgia—Temozolomide—brain cancer	0.000152	0.00098	CcSEcCtD
Fluvoxamine—Myalgia—Temozolomide—brain cancer	0.000152	0.00098	CcSEcCtD
Fluvoxamine—Rash—Procarbazine—brain cancer	0.000152	0.000979	CcSEcCtD
Fluvoxamine—Dermatitis—Procarbazine—brain cancer	0.000152	0.000978	CcSEcCtD
Fluvoxamine—Anxiety—Temozolomide—brain cancer	0.000151	0.000976	CcSEcCtD
Fluvoxamine—Headache—Procarbazine—brain cancer	0.000151	0.000973	CcSEcCtD
Fluvoxamine—Oedema—Carmustine—brain cancer	0.000151	0.000972	CcSEcCtD
Fluvoxamine—Discomfort—Temozolomide—brain cancer	0.00015	0.000968	CcSEcCtD
Fluvoxamine—Infection—Carmustine—brain cancer	0.00015	0.000965	CcSEcCtD
Fluvoxamine—Angiopathy—Etoposide—brain cancer	0.000149	0.00096	CcSEcCtD
Fluvoxamine—Dry mouth—Temozolomide—brain cancer	0.000148	0.000958	CcSEcCtD
Fluvoxamine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000148	0.0034	CbGpPWpGaD
Fluvoxamine—ABCB1—telencephalon—brain cancer	0.000148	0.0072	CbGeAlD
Fluvoxamine—CYP2E1—central nervous system—brain cancer	0.000147	0.00718	CbGeAlD
Fluvoxamine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—SKP2—brain cancer	0.000147	0.00338	CbGpPWpGaD
Fluvoxamine—Thrombocytopenia—Carmustine—brain cancer	0.000147	0.000952	CcSEcCtD
Fluvoxamine—Body temperature increased—Hydroxyurea—brain cancer	0.000147	0.00095	CcSEcCtD
Fluvoxamine—Chills—Etoposide—brain cancer	0.000147	0.000949	CcSEcCtD
Fluvoxamine—Tachycardia—Carmustine—brain cancer	0.000147	0.000948	CcSEcCtD
Fluvoxamine—Confusional state—Temozolomide—brain cancer	0.000147	0.000947	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Temozolomide—brain cancer	0.000145	0.000939	CcSEcCtD
Fluvoxamine—Oedema—Temozolomide—brain cancer	0.000145	0.000939	CcSEcCtD
Fluvoxamine—Alopecia—Etoposide—brain cancer	0.000145	0.000935	CcSEcCtD
Fluvoxamine—Infection—Temozolomide—brain cancer	0.000145	0.000933	CcSEcCtD
Fluvoxamine—CYP2E1—cerebellum—brain cancer	0.000144	0.00702	CbGeAlD
Fluvoxamine—Anorexia—Carmustine—brain cancer	0.000143	0.000926	CcSEcCtD
Fluvoxamine—Nausea—Procarbazine—brain cancer	0.000143	0.000923	CcSEcCtD
Fluvoxamine—Nervous system disorder—Temozolomide—brain cancer	0.000143	0.000921	CcSEcCtD
Fluvoxamine—Thrombocytopenia—Temozolomide—brain cancer	0.000142	0.00092	CcSEcCtD
Fluvoxamine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C9—brain cancer	0.000141	0.00323	CbGpPWpGaD
Fluvoxamine—Hypotension—Carmustine—brain cancer	0.000141	0.000908	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Temozolomide—brain cancer	0.000141	0.000908	CcSEcCtD
Fluvoxamine—Dysgeusia—Etoposide—brain cancer	0.00014	0.000902	CcSEcCtD
Fluvoxamine—CYP3A4—Oxidation by Cytochrome P450—CYP2C9—brain cancer	0.000139	0.00319	CbGpPWpGaD
Fluvoxamine—Anorexia—Temozolomide—brain cancer	0.000139	0.000895	CcSEcCtD
Fluvoxamine—Back pain—Etoposide—brain cancer	0.000138	0.000891	CcSEcCtD
Fluvoxamine—Hypersensitivity—Hydroxyurea—brain cancer	0.000137	0.000886	CcSEcCtD
Fluvoxamine—Musculoskeletal discomfort—Carmustine—brain cancer	0.000137	0.000885	CcSEcCtD
Fluvoxamine—Muscle spasms—Etoposide—brain cancer	0.000137	0.000885	CcSEcCtD
Fluvoxamine—Insomnia—Carmustine—brain cancer	0.000136	0.000879	CcSEcCtD
Fluvoxamine—Paraesthesia—Carmustine—brain cancer	0.000135	0.000873	CcSEcCtD
Fluvoxamine—Dyspnoea—Carmustine—brain cancer	0.000134	0.000866	CcSEcCtD
Fluvoxamine—Somnolence—Carmustine—brain cancer	0.000134	0.000864	CcSEcCtD
Fluvoxamine—Asthenia—Hydroxyurea—brain cancer	0.000134	0.000863	CcSEcCtD
Fluvoxamine—CYP2B6—Biological oxidations—CYP2C9—brain cancer	0.000134	0.00306	CbGpPWpGaD
Fluvoxamine—Musculoskeletal discomfort—Temozolomide—brain cancer	0.000133	0.000856	CcSEcCtD
Fluvoxamine—Ill-defined disorder—Etoposide—brain cancer	0.000132	0.000854	CcSEcCtD
Fluvoxamine—Anaemia—Etoposide—brain cancer	0.000132	0.000851	CcSEcCtD
Fluvoxamine—CYP2B6—Metapathway biotransformation—CYP2C9—brain cancer	0.000132	0.00302	CbGpPWpGaD
Fluvoxamine—CYP3A4—endocrine gland—brain cancer	0.000132	0.00641	CbGeAlD
Fluvoxamine—Insomnia—Temozolomide—brain cancer	0.000132	0.000849	CcSEcCtD
Fluvoxamine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDK6—brain cancer	0.000131	0.00301	CbGpPWpGaD
Fluvoxamine—Decreased appetite—Carmustine—brain cancer	0.000131	0.000845	CcSEcCtD
Fluvoxamine—CYP2E1—Biological oxidations—CYP2C9—brain cancer	0.000131	0.003	CbGpPWpGaD
Fluvoxamine—Paraesthesia—Temozolomide—brain cancer	0.000131	0.000843	CcSEcCtD
Fluvoxamine—CYP3A5—Biological oxidations—CYP2C9—brain cancer	0.000131	0.00299	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—ESR2—brain cancer	0.00013	0.00298	CbGpPWpGaD
Fluvoxamine—Gastrointestinal disorder—Carmustine—brain cancer	0.00013	0.000839	CcSEcCtD
Fluvoxamine—Dyspnoea—Temozolomide—brain cancer	0.00013	0.000837	CcSEcCtD
Fluvoxamine—CYP2D6—endocrine gland—brain cancer	0.00013	0.00631	CbGeAlD
Fluvoxamine—Somnolence—Temozolomide—brain cancer	0.000129	0.000835	CcSEcCtD
Fluvoxamine—CYP2E1—Metapathway biotransformation—CYP2C9—brain cancer	0.000129	0.00296	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metapathway biotransformation—CYP2C9—brain cancer	0.000129	0.00295	CbGpPWpGaD
Fluvoxamine—Pain—Carmustine—brain cancer	0.000129	0.000831	CcSEcCtD
Fluvoxamine—Constipation—Carmustine—brain cancer	0.000129	0.000831	CcSEcCtD
Fluvoxamine—Malaise—Etoposide—brain cancer	0.000129	0.00083	CcSEcCtD
Fluvoxamine—CYP1A1—brain—brain cancer	0.000128	0.00625	CbGeAlD
Fluvoxamine—Vertigo—Etoposide—brain cancer	0.000128	0.000827	CcSEcCtD
Fluvoxamine—Dyspepsia—Temozolomide—brain cancer	0.000128	0.000827	CcSEcCtD
Fluvoxamine—CYP2D6—head—brain cancer	0.000128	0.00623	CbGeAlD
Fluvoxamine—Leukopenia—Etoposide—brain cancer	0.000128	0.000824	CcSEcCtD
Fluvoxamine—Diarrhoea—Hydroxyurea—brain cancer	0.000127	0.000823	CcSEcCtD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	0.000127	0.00292	CbGpPWpGaD
Fluvoxamine—Decreased appetite—Temozolomide—brain cancer	0.000126	0.000816	CcSEcCtD
Fluvoxamine—SLC6A3—Dopaminergic Neurogenesis—STAT3—brain cancer	0.000126	0.00289	CbGpPWpGaD
Fluvoxamine—Gastrointestinal disorder—Temozolomide—brain cancer	0.000126	0.000811	CcSEcCtD
Fluvoxamine—Fatigue—Temozolomide—brain cancer	0.000125	0.00081	CcSEcCtD
Fluvoxamine—Loss of consciousness—Etoposide—brain cancer	0.000125	0.000809	CcSEcCtD
Fluvoxamine—CYP2B6—brain—brain cancer	0.000125	0.00608	CbGeAlD
Fluvoxamine—Cough—Etoposide—brain cancer	0.000124	0.000804	CcSEcCtD
Fluvoxamine—Pain—Temozolomide—brain cancer	0.000124	0.000803	CcSEcCtD
Fluvoxamine—Constipation—Temozolomide—brain cancer	0.000124	0.000803	CcSEcCtD
Fluvoxamine—Feeling abnormal—Carmustine—brain cancer	0.000124	0.000801	CcSEcCtD
Fluvoxamine—Convulsion—Etoposide—brain cancer	0.000124	0.000798	CcSEcCtD
Fluvoxamine—CYP1A1—Biological oxidations—CYP2C9—brain cancer	0.000123	0.00283	CbGpPWpGaD
Fluvoxamine—ABCB1—gonad—brain cancer	0.000123	0.00601	CbGeAlD
Fluvoxamine—Hypertension—Etoposide—brain cancer	0.000123	0.000795	CcSEcCtD
Fluvoxamine—Dizziness—Hydroxyurea—brain cancer	0.000123	0.000795	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Carmustine—brain cancer	0.000123	0.000795	CcSEcCtD
Fluvoxamine—CYP1A1—Metapathway biotransformation—CYP2C9—brain cancer	0.000122	0.00279	CbGpPWpGaD
Fluvoxamine—Chest pain—Etoposide—brain cancer	0.000121	0.000784	CcSEcCtD
Fluvoxamine—ABCB1—pituitary gland—brain cancer	0.00012	0.00586	CbGeAlD
Fluvoxamine—Discomfort—Etoposide—brain cancer	0.00012	0.000775	CcSEcCtD
Fluvoxamine—Feeling abnormal—Temozolomide—brain cancer	0.00012	0.000774	CcSEcCtD
Fluvoxamine—CYP3A4—Irinotecan Pathway—APC—brain cancer	0.00012	0.00275	CbGpPWpGaD
Fluvoxamine—Body temperature increased—Carmustine—brain cancer	0.000119	0.000768	CcSEcCtD
Fluvoxamine—Abdominal pain—Carmustine—brain cancer	0.000119	0.000768	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Temozolomide—brain cancer	0.000119	0.000768	CcSEcCtD
Fluvoxamine—CYP3A4—central nervous system—brain cancer	0.000119	0.00578	CbGeAlD
Fluvoxamine—Vomiting—Hydroxyurea—brain cancer	0.000118	0.000764	CcSEcCtD
Fluvoxamine—Rash—Hydroxyurea—brain cancer	0.000117	0.000758	CcSEcCtD
Fluvoxamine—Confusional state—Etoposide—brain cancer	0.000117	0.000758	CcSEcCtD
Fluvoxamine—Dermatitis—Hydroxyurea—brain cancer	0.000117	0.000757	CcSEcCtD
Fluvoxamine—CYP2E1—brain—brain cancer	0.000117	0.0057	CbGeAlD
Fluvoxamine—CYP2D6—central nervous system—brain cancer	0.000117	0.00569	CbGeAlD
Fluvoxamine—Headache—Hydroxyurea—brain cancer	0.000117	0.000753	CcSEcCtD
Fluvoxamine—Anaphylactic shock—Etoposide—brain cancer	0.000116	0.000752	CcSEcCtD
Fluvoxamine—ABCB1—medulla oblongata—brain cancer	0.000116	0.00566	CbGeAlD
Fluvoxamine—Infection—Etoposide—brain cancer	0.000116	0.000747	CcSEcCtD
Fluvoxamine—Urticaria—Temozolomide—brain cancer	0.000116	0.000746	CcSEcCtD
Fluvoxamine—Body temperature increased—Temozolomide—brain cancer	0.000115	0.000742	CcSEcCtD
Fluvoxamine—Abdominal pain—Temozolomide—brain cancer	0.000115	0.000742	CcSEcCtD
Fluvoxamine—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C9—brain cancer	0.000114	0.00262	CbGpPWpGaD
Fluvoxamine—CYP2D6—cerebellum—brain cancer	0.000114	0.00556	CbGeAlD
Fluvoxamine—Thrombocytopenia—Etoposide—brain cancer	0.000114	0.000736	CcSEcCtD
Fluvoxamine—Tachycardia—Etoposide—brain cancer	0.000114	0.000733	CcSEcCtD
Fluvoxamine—Hyperhidrosis—Etoposide—brain cancer	0.000113	0.000726	CcSEcCtD
Fluvoxamine—Anorexia—Etoposide—brain cancer	0.000111	0.000716	CcSEcCtD
Fluvoxamine—Hypersensitivity—Carmustine—brain cancer	0.000111	0.000716	CcSEcCtD
Fluvoxamine—Nausea—Hydroxyurea—brain cancer	0.000111	0.000714	CcSEcCtD
Fluvoxamine—Hypotension—Etoposide—brain cancer	0.000109	0.000702	CcSEcCtD
Fluvoxamine—Asthenia—Carmustine—brain cancer	0.000108	0.000697	CcSEcCtD
Fluvoxamine—Hypersensitivity—Temozolomide—brain cancer	0.000107	0.000692	CcSEcCtD
Fluvoxamine—CYP3A4—Farnesoid X Receptor  Pathway—IRS2—brain cancer	0.000106	0.00243	CbGpPWpGaD
Fluvoxamine—ABCB1—midbrain—brain cancer	0.000106	0.00517	CbGeAlD
Fluvoxamine—Paraesthesia—Etoposide—brain cancer	0.000105	0.000675	CcSEcCtD
Fluvoxamine—Asthenia—Temozolomide—brain cancer	0.000104	0.000674	CcSEcCtD
Fluvoxamine—Dyspnoea—Etoposide—brain cancer	0.000104	0.00067	CcSEcCtD
Fluvoxamine—ABCB1—spinal cord—brain cancer	0.000104	0.00504	CbGeAlD
Fluvoxamine—Somnolence—Etoposide—brain cancer	0.000103	0.000668	CcSEcCtD
Fluvoxamine—Diarrhoea—Carmustine—brain cancer	0.000103	0.000665	CcSEcCtD
Fluvoxamine—Pruritus—Temozolomide—brain cancer	0.000103	0.000664	CcSEcCtD
Fluvoxamine—Decreased appetite—Etoposide—brain cancer	0.000101	0.000653	CcSEcCtD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—HES1—brain cancer	0.000101	0.00232	CbGpPWpGaD
Fluvoxamine—CYP2C19—Biological oxidations—CYP2C9—brain cancer	0.000101	0.00231	CbGpPWpGaD
Fluvoxamine—Gastrointestinal disorder—Etoposide—brain cancer	0.000101	0.000649	CcSEcCtD
Fluvoxamine—Fatigue—Etoposide—brain cancer	0.0001	0.000648	CcSEcCtD
Fluvoxamine—CYP2C19—Metapathway biotransformation—CYP2C9—brain cancer	9.96e-05	0.00228	CbGpPWpGaD
Fluvoxamine—Dizziness—Carmustine—brain cancer	9.96e-05	0.000643	CcSEcCtD
Fluvoxamine—Constipation—Etoposide—brain cancer	9.96e-05	0.000643	CcSEcCtD
Fluvoxamine—Pain—Etoposide—brain cancer	9.96e-05	0.000643	CcSEcCtD
Fluvoxamine—Diarrhoea—Temozolomide—brain cancer	9.95e-05	0.000643	CcSEcCtD
Fluvoxamine—CYP1A2—Estrogen Receptor Pathway—STAT3—brain cancer	9.75e-05	0.00224	CbGpPWpGaD
Fluvoxamine—Dizziness—Temozolomide—brain cancer	9.62e-05	0.000621	CcSEcCtD
Fluvoxamine—Feeling abnormal—Etoposide—brain cancer	9.59e-05	0.000619	CcSEcCtD
Fluvoxamine—Vomiting—Carmustine—brain cancer	9.57e-05	0.000618	CcSEcCtD
Fluvoxamine—Gastrointestinal pain—Etoposide—brain cancer	9.52e-05	0.000615	CcSEcCtD
Fluvoxamine—Rash—Carmustine—brain cancer	9.49e-05	0.000613	CcSEcCtD
Fluvoxamine—Dermatitis—Carmustine—brain cancer	9.48e-05	0.000612	CcSEcCtD
Fluvoxamine—Headache—Carmustine—brain cancer	9.43e-05	0.000609	CcSEcCtD
Fluvoxamine—ABCB1—endocrine gland—brain cancer	9.32e-05	0.00454	CbGeAlD
Fluvoxamine—CYP2D6—Biological oxidations—CYP2C9—brain cancer	9.29e-05	0.00213	CbGpPWpGaD
Fluvoxamine—CYP2D6—brain—brain cancer	9.27e-05	0.00452	CbGeAlD
Fluvoxamine—Vomiting—Temozolomide—brain cancer	9.25e-05	0.000597	CcSEcCtD
Fluvoxamine—Urticaria—Etoposide—brain cancer	9.25e-05	0.000597	CcSEcCtD
Fluvoxamine—ABCB1—head—brain cancer	9.2e-05	0.00448	CbGeAlD
Fluvoxamine—Abdominal pain—Etoposide—brain cancer	9.2e-05	0.000594	CcSEcCtD
Fluvoxamine—Body temperature increased—Etoposide—brain cancer	9.2e-05	0.000594	CcSEcCtD
Fluvoxamine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—brain cancer	9.2e-05	0.00211	CbGpPWpGaD
Fluvoxamine—Rash—Temozolomide—brain cancer	9.17e-05	0.000592	CcSEcCtD
Fluvoxamine—Dermatitis—Temozolomide—brain cancer	9.16e-05	0.000592	CcSEcCtD
Fluvoxamine—CYP2D6—Metapathway biotransformation—CYP2C9—brain cancer	9.16e-05	0.0021	CbGpPWpGaD
Fluvoxamine—Headache—Temozolomide—brain cancer	9.11e-05	0.000588	CcSEcCtD
Fluvoxamine—Nausea—Carmustine—brain cancer	8.94e-05	0.000577	CcSEcCtD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—S100A10—brain cancer	8.74e-05	0.002	CbGpPWpGaD
Fluvoxamine—Nausea—Temozolomide—brain cancer	8.64e-05	0.000558	CcSEcCtD
Fluvoxamine—Hypersensitivity—Etoposide—brain cancer	8.58e-05	0.000554	CcSEcCtD
Fluvoxamine—SLC6A4—Circadian rythm related genes—SIRT1—brain cancer	8.56e-05	0.00196	CbGpPWpGaD
Fluvoxamine—ABCB1—central nervous system—brain cancer	8.4e-05	0.00409	CbGeAlD
Fluvoxamine—Asthenia—Etoposide—brain cancer	8.35e-05	0.000539	CcSEcCtD
Fluvoxamine—Pruritus—Etoposide—brain cancer	8.24e-05	0.000532	CcSEcCtD
Fluvoxamine—ABCB1—cerebellum—brain cancer	8.21e-05	0.004	CbGeAlD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—brain cancer	8.11e-05	0.00186	CbGpPWpGaD
Fluvoxamine—Diarrhoea—Etoposide—brain cancer	7.97e-05	0.000514	CcSEcCtD
Fluvoxamine—CYP1A2—Biological oxidations—CYP2C9—brain cancer	7.87e-05	0.0018	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metapathway biotransformation—CYP2C9—brain cancer	7.76e-05	0.00178	CbGpPWpGaD
Fluvoxamine—Dizziness—Etoposide—brain cancer	7.7e-05	0.000497	CcSEcCtD
Fluvoxamine—Vomiting—Etoposide—brain cancer	7.4e-05	0.000478	CcSEcCtD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—RELA—brain cancer	7.34e-05	0.00168	CbGpPWpGaD
Fluvoxamine—Rash—Etoposide—brain cancer	7.34e-05	0.000474	CcSEcCtD
Fluvoxamine—Dermatitis—Etoposide—brain cancer	7.33e-05	0.000473	CcSEcCtD
Fluvoxamine—Headache—Etoposide—brain cancer	7.29e-05	0.000471	CcSEcCtD
Fluvoxamine—Nausea—Etoposide—brain cancer	6.91e-05	0.000446	CcSEcCtD
Fluvoxamine—ABCB1—brain—brain cancer	6.67e-05	0.00325	CbGeAlD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	6.61e-05	0.00152	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—CDK4—brain cancer	6.47e-05	0.00148	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—PDGFRA—brain cancer	6.28e-05	0.00144	CbGpPWpGaD
Fluvoxamine—CYP3A4—Biological oxidations—CYP2C9—brain cancer	6.07e-05	0.00139	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metapathway biotransformation—CYP2C9—brain cancer	5.99e-05	0.00137	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	5.62e-05	0.00129	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—brain cancer	5.24e-05	0.0012	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—MYC—brain cancer	5.17e-05	0.00119	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—brain cancer	5.07e-05	0.00116	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	5.06e-05	0.00116	CbGpPWpGaD
Fluvoxamine—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—brain cancer	5.06e-05	0.00116	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—brain cancer	4.96e-05	0.00114	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	4.74e-05	0.00109	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—RELA—brain cancer	4.68e-05	0.00107	CbGpPWpGaD
Fluvoxamine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—brain cancer	4.46e-05	0.00102	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—S100A10—brain cancer	4.34e-05	0.000995	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—brain cancer	4.22e-05	0.000966	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—brain cancer	4.19e-05	0.000961	CbGpPWpGaD
Fluvoxamine—SLC6A3—Transmembrane transport of small molecules—TRPC6—brain cancer	4.03e-05	0.000925	CbGpPWpGaD
Fluvoxamine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—brain cancer	3.93e-05	0.0009	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.88e-05	0.000889	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—brain cancer	3.58e-05	0.000821	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—IDH1—brain cancer	3.46e-05	0.000794	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—brain cancer	3.44e-05	0.000789	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—IL2—brain cancer	3.43e-05	0.000785	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—SIRT1—brain cancer	3.37e-05	0.000774	CbGpPWpGaD
Fluvoxamine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—brain cancer	3.36e-05	0.000771	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—brain cancer	3.33e-05	0.000764	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—brain cancer	3.3e-05	0.000756	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—brain cancer	3.22e-05	0.000739	CbGpPWpGaD
Fluvoxamine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—brain cancer	3.22e-05	0.000739	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—brain cancer	3.1e-05	0.00071	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—CYP2C9—brain cancer	3.09e-05	0.000708	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP2C9—brain cancer	3.02e-05	0.000693	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—brain cancer	2.95e-05	0.000677	CbGpPWpGaD
Fluvoxamine—ABCB1—Allograft Rejection—VEGFA—brain cancer	2.91e-05	0.000668	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.83e-05	0.00065	CbGpPWpGaD
Fluvoxamine—SLC6A4—Circadian rythm related genes—TP53—brain cancer	2.75e-05	0.000631	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—BSG—brain cancer	2.63e-05	0.000602	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.58e-05	0.000593	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—brain cancer	2.55e-05	0.000585	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—APC—brain cancer	2.4e-05	0.000551	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—CYP2C9—brain cancer	2.28e-05	0.000524	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—IDH1—brain cancer	2.26e-05	0.000518	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—CYP2C9—brain cancer	2.24e-05	0.000513	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—CYP2C9—brain cancer	2.23e-05	0.000512	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—IDH1—brain cancer	2.21e-05	0.000506	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—CYP2C9—brain cancer	2.11e-05	0.000484	CbGpPWpGaD
Fluvoxamine—ABCB1—Transmembrane transport of small molecules—TRPC6—brain cancer	2.01e-05	0.00046	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—BSG—brain cancer	1.94e-05	0.000445	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—BSG—brain cancer	1.9e-05	0.000436	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—BSG—brain cancer	1.9e-05	0.000435	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—brain cancer	1.87e-05	0.000428	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—BSG—brain cancer	1.79e-05	0.000411	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—ENO2—brain cancer	1.79e-05	0.000409	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—CYP2C9—brain cancer	1.73e-05	0.000396	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—CYP2C9—brain cancer	1.69e-05	0.000386	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—IDH1—brain cancer	1.67e-05	0.000383	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—brain cancer	1.65e-05	0.000378	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—IDH1—brain cancer	1.64e-05	0.000375	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—IDH1—brain cancer	1.63e-05	0.000374	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—brain cancer	1.63e-05	0.000374	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—CYP2C9—brain cancer	1.59e-05	0.000364	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—IDH1—brain cancer	1.54e-05	0.000354	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—BSG—brain cancer	1.47e-05	0.000337	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—brain cancer	1.44e-05	0.000329	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—BSG—brain cancer	1.43e-05	0.000329	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—BSG—brain cancer	1.35e-05	0.00031	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—CYP2C9—brain cancer	1.35e-05	0.000308	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—BSG—brain cancer	1.34e-05	0.000307	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—brain cancer	1.32e-05	0.000303	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—ENO2—brain cancer	1.32e-05	0.000303	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—ENO2—brain cancer	1.29e-05	0.000297	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—brain cancer	1.29e-05	0.000296	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—ENO2—brain cancer	1.29e-05	0.000296	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—IDH1—brain cancer	1.26e-05	0.000289	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.26e-05	0.000288	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—IDH1—brain cancer	1.23e-05	0.000282	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—ENO2—brain cancer	1.22e-05	0.00028	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—IDH1—brain cancer	1.16e-05	0.000266	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—IDH1—brain cancer	1.15e-05	0.000264	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—BSG—brain cancer	1.14e-05	0.000262	CbGpPWpGaD
Fluvoxamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—brain cancer	1.09e-05	0.000249	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—CYP2C9—brain cancer	1.04e-05	0.000238	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	1.03e-05	0.000236	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—ENO2—brain cancer	9.98e-06	0.000229	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—IDH1—brain cancer	9.84e-06	0.000226	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—ENO2—brain cancer	9.74e-06	0.000223	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	9.37e-06	0.000215	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—ENO2—brain cancer	9.18e-06	0.00021	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—ENO2—brain cancer	9.1e-06	0.000209	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—BSG—brain cancer	8.83e-06	0.000202	CbGpPWpGaD
Fluvoxamine—CYP3A7—Metabolism—PIK3CG—brain cancer	8.19e-06	0.000188	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—brain cancer	8.01e-06	0.000184	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—ENO2—brain cancer	7.78e-06	0.000178	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—IDH1—brain cancer	7.59e-06	0.000174	CbGpPWpGaD
Fluvoxamine—CYP2B6—Metabolism—PIK3CG—brain cancer	6.06e-06	0.000139	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—ENO2—brain cancer	6e-06	0.000138	CbGpPWpGaD
Fluvoxamine—CYP2E1—Metabolism—PIK3CG—brain cancer	5.93e-06	0.000136	CbGpPWpGaD
Fluvoxamine—CYP3A5—Metabolism—PIK3CG—brain cancer	5.92e-06	0.000136	CbGpPWpGaD
Fluvoxamine—CYP1A1—Metabolism—PIK3CG—brain cancer	5.59e-06	0.000128	CbGpPWpGaD
Fluvoxamine—CYP2C19—Metabolism—PIK3CG—brain cancer	4.58e-06	0.000105	CbGpPWpGaD
Fluvoxamine—ABCB1—Metabolism—PIK3CG—brain cancer	4.47e-06	0.000102	CbGpPWpGaD
Fluvoxamine—CYP2D6—Metabolism—PIK3CG—brain cancer	4.21e-06	9.65e-05	CbGpPWpGaD
Fluvoxamine—CYP2C9—Metabolism—PIK3CG—brain cancer	4.17e-06	9.57e-05	CbGpPWpGaD
Fluvoxamine—CYP1A2—Metabolism—PIK3CG—brain cancer	3.57e-06	8.18e-05	CbGpPWpGaD
Fluvoxamine—CYP3A4—Metabolism—PIK3CG—brain cancer	2.75e-06	6.31e-05	CbGpPWpGaD
